Open AccessEnergy metabolism regulators effect on clinical course and inflammatory markers in patients with exacerbation of severe copd
Author(s) -
Maria Sanzharovskaya,
N. V. Varvyanskaya,
N. S. Yamkina,
I. N. Pechyorkina,
А. А. Смотрова,
С. И. Антипов,
Ye. P. Roslyakova,
O. Ye. Akbasheva,
O. P. Sanzharovskaya,
В. А. Хазанов,
G. E. Chernogoryuk
Publication year - 2008
Publication title -
bûlletenʹ sibirskoj mediciny
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.135
H-Index - 3
eISSN - 1819-3684
pISSN - 1682-0363
DOI - 10.20538/1682-0363-2008-3-109-116
Subject(s) - medicine , spirometry , exacerbation , copd , sputum , placebo , prospective cohort study , clinical trial , anesthesia , pathology , asthma , tuberculosis , alternative medicine
We assessed in a prospective, randomised, placebo-controlled trial the effects of «yantar-antitox» in patients with exacerbations of COPD requiring hospital admission. We recruited patients with exacerbations of severe COPD who were randomly assigned oral «Yantar-antitox» (n=33) or identical placebo (n=45) for 14 days, in addition to standard treatment with nebulised bronchodilators, antibiotics, and oxygen. We did spirometry and recorded symptom scores in inpatients. The 6-min walking distance (6MWD) was also determined. Inflammatory markers were measured in induced sputum and serum. Significant increase in the percentage predicted lung vital capacity, maximal expiratory flow volume, 6MWD were found between the patient in the «Yantar-antitox» — treated group.